Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union [Yahoo! Fina...
X4 Pharmaceuticals, Inc. (XFOR)
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
EC approval marks a significant milestone for people living with this ultra-rare primary immunodeficiency and was granted under exceptional circumstances Norgine to lead commercialisation across Europe under its agreement with X4 Pharmaceuticals AMSTERDAM April 29, 2026 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company, today announced that the European Commission (EC) has granted marketing authorisation for mavorixafor as XOLREMDI ® following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The marketing authorisation was granted under exceptional circumstances*, reflecting the ultra-rare nature of WHIM syndrome. Norgine Logo (PRNewsfoto/Norgine Pharmaceuticals Limited) XOLREMDI ® is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and ly
Show less
Read more
Impact Snapshot
Event Time:
XFOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XFOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XFOR alerts
High impacting X4 Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
XFOR
News
- X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionGlobeNewswire
- X4 Pharmaceuticals (XFOR) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (e+)" to "sell (d-)".MarketBeat
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- X4 Pharmaceuticals (XFOR) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- X4 Pharmaceuticals (XFOR) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=XFOR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell"MarketBeat
XFOR
Earnings
- 5/1/25 - Beat
XFOR
Sec Filings
- 3/20/26 - Form ARS
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- XFOR's page on the SEC website